Oruka Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Menlo Park, CA
ORKA chart
What traders are saying about $ORKA
Latest postsOruka Therapeutics, Inc. news
- Oruka Therapeutics, Inc. - Common Stock (ORKA) Stock Price, News, Quote & History
FinancialContent ·
- Oruka Therapeutics (ORKA) Looks Fully Priced Following Strong EVERLAST B Psoriasis Trial Data
Simply Wall Street ·
- H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data
Investing.com ·
- Oruka Therapeutics, Inc. (ORKA) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results
Yahoo Finance ·
- Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
marketbeat.com ·
- ORKA Stock Grinds Higher As Cash War Chest Draws Trader Focus
StocksToTrade ·
- ORKA Stock Grinds Higher As Cash War Chest Fuels Speculation
Timothy Sykes ·
- Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift”
tikr.com ·
- Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow (NASDAQ:ORKA) 2026-10-26
Seeking Alpha ·
- Oruka Therapeutics Stock Soars - Here's Why - Oruka Therapeutics (NASDAQ:ORKA)
Benzinga ·
- Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months
stocktwits.com ·
Oruka Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $0 | $0 |
| Net income | -$105.4M | -$83.7M | -$5.3M | -$9.9M |
| Diluted EPS | – | $-3.87 | $-0.37 | $-0.69 |
| Total assets (year end) | $488.6M | $396.0M | $37.9M | $43.1M |
| Cash and equivalents (year end) | $46.9M | $61.6M | $37.4M | $42.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- DEF 14APROXY STATEMENT
- 10-KANNUAL REPORT
- 8-KCURRENT REPORT
About Oruka Therapeutics, Inc.
- Ticker
- ORKA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Menlo Park, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 907654
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
Frequently asked questions
What exchange is Oruka Therapeutics, Inc. listed on?
Oruka Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ORKA.
What industry is Oruka Therapeutics, Inc. in?
Oruka Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Oruka Therapeutics, Inc. headquartered?
Oruka Therapeutics, Inc.'s business address on file with the SEC is in Menlo Park, CA.
When does Oruka Therapeutics, Inc.'s fiscal year end?
Oruka Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Oruka Therapeutics, Inc. report?
Oruka Therapeutics, Inc. reported $0 in revenue for calendar year 2023, according to its SEC filings.